iConnectHub
Access
Login/Register
Supplier Login
BOSTON -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company will be expanding its MammoView Breast Endoscopy product line and will be marketing its MammoView Breast Endoscopy Components to hospitals across the Country and Internationally through direct sales channels.
The MammoView line currently contains 6 unique Breast Endoscopy Components. Solos Endoscopy instruments are FDA approved. Upon receipt of its ISO 13485 Certification, the company will be able to place the CE Mark on its entire instrument line which will allow it to market the MammoView? Breast Endoscopy Components Internationally.
"Solos is putting added emphasis on its MammoView line of breast endoscopy instrumentation by developing new instruments which will include a new biopsy device to complement its existing line and is in the process of obtaining the necessary regulatory approvals to broaden our markets," Solos president Bob Segersten said.
The MammoView Breast Endoscopy System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of the breast cancers arise. Solos' intraductal devices are designed to provide direct observation with any endoscopic video system while providing unprecedented image quality, using advanced minimally invasive technologies and tissue preservation techniques.
The MammoView instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.
ADIDAS